Breast Cancer Survivors with Genitourinary Syndrome of Menopause Receiving Aromatase Inhibitors Are Willing to Sexual Assessment: Is a Dyspareunia Approach Enough?
Table 1
Baseline characteristics of the overall sample, as well as according to sexual activity.
All patients (N = 83)
Sexually active (n = 59)
Non-sexually active (n = 24)
value
Age (years), mean ± sd (range)
52.9 ± 8.6 (33–70)
51.6 ± 8.7 (33–70)
56 ± 7.7 (42–67)
0.0361
Ethnicity
(i) White/Caucasian, n (%)
77 (92.8)
55 (93.2)
22 (91.7)
0.562
(ii) Latino American/Hispanic, n (%)
6 (7.2)
4 (6.8)
2 (8.3)
Occupation
(i) Unemployed, n (%)
4 (5.1)
3 (5.5)
1 (4.3)
0.4913
(ii) Employed, n (%)
39 (50)
27 (49.1)
12 (52.2)
(iii) Sick leave, n (%)
15 (19.2)
11 (20)
4 (17.4)
(iv) Incapacity, n (%)
9 (11.5)
5 (9.1)
4 (17.4)
(v) Retired, n (%)
11 (14.1)
9 (16.4)
2 (8.7)
Missing, n
5
4
1
Smokers, n (%)
10 (12.1)
7 (11.9)
3 (12.5)
0.9367
Children
(i) No, n (%)
20 (24.4)
13 (22.4)
7 (29.2)
0.5230
(ii) Yes, n (%)
62 (75.6)
45 (77.6)
17 (70.8)
Missing, n
1
1
0
BMI (kg/m2), mean ± sd (range)
24.5 ± 4.1 (18–40.9)
24.1 ± 3.8 (18–34.2)
25.6 ± 4.7 (19.1–40.9)
0.1158
Age of menopause (years), mean ± sd (range)
45.4 ± 6.4 (22.5–57)
45.1 ± 5.7 (31–56)
46.2 ± 8 (22–56)
0.4827
(i) Natural menopause, n (%)
29 (35.4)
17 (29.3)
12 (50)
(ii) Induced menopause, n (%)
53 (64.6)
41 (70.7)
12 (50)
0.0762
Missing, n
1
1
0
Serum oestradiol (pg/ml), mean ± sd (range)
13.0 ± 35.5
7.2 ± 13.8
35.2 ± 7.3
0.03
Metabolic diseases
(i) Hypertension, n (%)
18 (21.9)
14 (24.1)
4 (16.7)
0.56
(ii) Diabetes, n (%)
4 (4.8)
3 (5.2)
1 (4.2)
0.66
(iii) Dyslipidemia, n (%)
18 (21.9)
12 (20.7)
6 (25)
0.77
Missing, n
1
1
0
Mental health
(i) No mental health issues, n (%)
50 (60.3)
41 (69.5)
9 (37.5)
0.023
(ii) Non-pharmacological management, n (%)
6 (7.2)
3 (5.1)
3 (12.5)
(iii) Pharmacological management, n (%)
27 (32.5)
15 (25.4)
12 (50)
BC stage
(i) Stage I, n (%)
32 (38.6)
21 (35.6)
11 (45.8)
0.347
(ii) Stage II, n (%)
43 (51.8)
32 (54.2)
11 (45.8)
(iii) Stage III, n (%)
7 (8.4)
6 (10.2)
1 (4.2)
(iv) Stage IV, n (%)
1 (1.2)
0
1 (4.2)
Treatment modalities
(i) Hormonal therapy, n (%)
83 (100)
59 (100)
24 (100)
—
(ii) GnRh analogues, n (%)
28 (34)
24 (40.6)
4 (16.7)
0.04
(iii) Surgery, n (%)
82 (98.8)
59 (100)
23 (95.8)
0.539
(iv) Chemotherapy, n (%)
67 (80.7)
49 (83.1)
18 (75)
0.4054
(v) Radiotherapy, n (%)
60 (72.3)
43 (72.88)
17 (70.8)
0.8523
VHI, mean ± sd (range)
10.5 ± 3.4 (0–21)
11.4 ± 3.5 (7.0–21.0)
8.9 ± 2.8 (0–14)
0.001
Vaginal pH, mean ± sd (range)
7.7 ± 0.9 (5–9)
7.6 ± 0.9 (5–9)
7.8 ± 0.8 (6–9)
0.7118
The bold values indicate the significant difference.
